On May 24, 2010 the Food and Drug Administration (FDA) approved Lumizyme for treatment of “patients 8 years and older with late (non-infantile) onset Pompe disease who do not have evidence of cardiac hypertrophy.”

For more information on the approval, and how to access treatment please read
Genzyme’s Pompe Program Update (PDF, 100 kB)